欧洲9国额颞叶变性相关综合征的发病率
FRONTIERS研究是一项回顾性队列研究,基于欧洲9国13家三级额颞叶变性研究诊所的人群登记,纳入2018年6月1日至2019年5月31日期间所有新发额颞叶变性相关病例,合计观察人年11 023 643。共识别267例患者,采用随机截距泊松模型估计欧洲额颞叶变性年发病率为2.36例/10万人年(95%CI 1.59-3.51),男性发病率高于女性。
要点
- 欧洲额颞叶变性年发病率估计为2.36例/10万人年(95%CI 1.59-3.51)。
- 发病率随年龄增长而升高,在71岁达峰。
- 行为变异型额颞叶痴呆是最常见表型(107例,40.07%)。
核心结论
- 研究提示额颞叶变性相关综合征比既往认识的更为常见,任何年龄均应考虑该诊断。
- 提高对额颞叶变性发病率的认识可能有助于合理的健康与社会照护规划及未来临床试验设计。
研究设计与样本
- FRONTIERS为回顾性队列研究,于2018年6月1日至2019年5月31日开展,数据于2021年7月19日至12月7日分析。
- 研究使用来自英国、荷兰、芬兰、瑞典、西班牙、保加利亚、塞尔维亚、德国和意大利13家三级额颞叶变性研究诊所的人群登记,纳入研究期间所有新发额颞叶变性相关病例,合计观察人年11 023 643。
- 纳入患者符合行为变异型额颞叶痴呆、原发性进行性失语非流利变异型或语义变异型、未特定原发性进行性失语、进行性核上性麻痹、皮质基底节综合征或额颞叶痴呆伴肌萎缩侧索硬化的诊断标准。
- 采用随机截距泊松模型估计考虑地理异质性的欧洲额颞叶变性发病率。
主要发现
- 共识别267例患者,平均(标准差)年龄66.70(9.02)岁,男性156例(58.43%)。
- 欧洲额颞叶变性年发病率估计为2.36例/10万人年(95%CI 1.59-3.51)。
- 发病率随年龄增长而升高,在71岁达峰,男性为13.09例/10万人年(95%CI 8.46-18.93),女性为7.88例/10万人年(95%CI 5.39-11.60)。
- 男性总体发病率(2.84例/10万人年;95%CI 1.88-4.27)高于女性(1.91例/10万人年;95%CI 1.26-2.91)。
- 行为变异型额颞叶痴呆为最常见表型(107例,40.07%),其次为原发性进行性失语(76例,28.46%)和锥体外系表型(69例,25.84%),额颞叶痴呆伴肌萎缩侧索硬化最少见(15例,5.62%)。
临床怎么用
- 原文结论指出,研究提示额颞叶变性相关综合征比既往认识的更为常见,任何年龄均应考虑该诊断。
- 原文结论指出,提高对额颞叶变性发病率的认识可能有助于合理的健康与社会照护规划及未来临床试验设计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Diagnostic incidence data for syndromes associated with frontotemporal lobar degeneration (FTLD) in multinational studies are urgent in light of upcoming therapeutic approaches. OBJECTIVE: To assess the incidence of FTLD across Europe. DESIGN, SETTING, AND PARTICIPANTS: The Frontotemporal Dementia Incidence European Research Study (FRONTIERS) was a retrospective cohort study conducted from June 1, 2018, to May 31, 2019, using a population-based registry from 13 tertiary FTLD research clinics from the UK, the Netherlands, Finland, Sweden, Spain, Bulgaria, Serbia, Germany, and Italy and including all new FTLD-associated cases during the study period, with a combined catchment population of 11 023 643 person-years. Included patients fulfilled criteria for the behavioral variant of frontotemporal dementia (BVFTD), the nonfluent variant or semantic variant of primary progressive aphasia (PPA), unspecified PPA, progressive supranuclear palsy, corticobasal syndrome, or frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Data were analyzed from July 19 to December 7, 2021. MAIN OUTCOMES AND MEASURES: Random-intercept Poisson models were used to obtain estimates of the European FTLD incidence rate accounting for geographic heterogeneity. RESULTS: Based on 267 identified cases (mean [SD] patient age, 66.70 [9.02] years; 156 males [58.43%]), the estimated annual incidence rate for FTLD in Europe was 2.36 cases per 100 000 person-years (95% CI, 1.59-3.51 cases per 100 000 person-years). There was a progressive increase in FTLD incidence across age, reaching its peak at the age of 71 years, with 13.09 cases per 100 000 person-years (95% CI, 8.46-18.93 cases per 100 000 person-years) among men and 7.88 cases per 100 000 person-years (95% CI, 5.39-11.60 cases per 100 000 person-years) among women. Overall, the incidence was higher among men (2.84 cases per 100 000 person-years; 95% CI, 1.88-4.27 cases per 100 000 person-years) than among women (1.91 cases per 100 000 person-years; 95% CI, 1.26-2.91 cases per 100 000 person-years). BVFTD was the most common phenotype (107 cases [40.07%]), followed by PPA (76 [28.46%]) and extrapyramidal phenotypes (69 [25.84%]). FTD-ALS was the rarest phenotype (15 cases [5.62%]). A total of 95 patients with FTLD (35.58%) had a family history of dementia. The estimated number of new FTLD cases per year in Europe was 12 057. CONCLUSIONS AND RELEVANCE: The findings suggest that FTLD-associated syndromes are more common than previously recognized, and diagnosis should be considered at any age. Improved knowledge of FTLD incidence may contribute to appropriate health and social care planning and in the design of future clinical trials.
引用
- Logroscino G, Piccininni M, Graff C, et al. Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries. JAMA Neurol. 2023. PMID: 36716024. doi:10.1001/jamaneurol.2022.5128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。